AP2B1 was shown to interact with ANO7 in prostate cancer patients, putatively promoting cancer progression [102], increasing chemotherapy resistance in ovarian cancer patients [103], upregulating cancer cell metastasis ability [104], while putatively acting as an anti-cancer agent in triple-negative breast cancer patients [105]. The gene discussed is AP2B1; the disease is cancer.